Matthew Keller
Stock Analyst at HC Wainwright & Co.
(n/a)
# 4,698
Out of 5,149 analysts
12
Total ratings
9.09%
Success rate
-33.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Keller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHIO Phio Pharmaceuticals | Reiterates: Buy | $14 | $1.02 | +1,272.55% | 2 | Feb 10, 2026 | |
| SXTP 60 Degrees Pharmaceuticals | Maintains: Buy | $6 → $24 | $3.04 | +689.47% | 2 | Jan 27, 2026 | |
| IFRX InflaRx | Reiterates: Buy | $6 | $0.92 | +552.10% | 2 | Dec 30, 2025 | |
| GALT Galectin Therapeutics | Maintains: Buy | $6 → $11 | $3.07 | +258.31% | 2 | Dec 17, 2025 | |
| SNSE Sensei Biotherapeutics | Downgrades: Neutral | n/a | $29.81 | - | 1 | Oct 30, 2025 | |
| ACXP Acurx Pharmaceuticals | Reiterates: Buy | $31 | $1.53 | +1,926.14% | 2 | Sep 30, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $18 | $8.76 | +105.48% | 1 | Aug 26, 2025 |
Phio Pharmaceuticals
Feb 10, 2026
Reiterates: Buy
Price Target: $14
Current: $1.02
Upside: +1,272.55%
60 Degrees Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $6 → $24
Current: $3.04
Upside: +689.47%
InflaRx
Dec 30, 2025
Reiterates: Buy
Price Target: $6
Current: $0.92
Upside: +552.10%
Galectin Therapeutics
Dec 17, 2025
Maintains: Buy
Price Target: $6 → $11
Current: $3.07
Upside: +258.31%
Sensei Biotherapeutics
Oct 30, 2025
Downgrades: Neutral
Price Target: n/a
Current: $29.81
Upside: -
Acurx Pharmaceuticals
Sep 30, 2025
Reiterates: Buy
Price Target: $31
Current: $1.53
Upside: +1,926.14%
Gyre Therapeutics
Aug 26, 2025
Initiates: Buy
Price Target: $18
Current: $8.76
Upside: +105.48%